![Sergey Yurasov](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vermögen: 53 462 $ am 31.05.2026
Sergey Yurasov currently works at Black Diamond Therapeutics, Inc., as Chief Medical Officer from 2022.
Dr. Yurasov also formerly worked at Hoffman-La Roche, Inc., as Clinical Director-Oncology & Pharma Research, ImClone LLC, as Associate Vice President-Global Medicine Science, The Rockefeller University, as Assistant Professor-Clinical Investigation, Immune Design Corp., as Chief Medical Officer & SVP-Clinical Development from 2016 to 2019, Clovis Oncology, Inc., as Senior Vice President-Clinical Development in 2016, and Nuvation Bio, Inc., as Chief Medical Officer from 2019 to 2022.
Dr. Yurasov received his doctorate degree from Russian State Medical University and doctorate degree from Research Institute for Pediatric Oncology.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 27.04.2026 | 24.082 ( 0,04 % ) | 53 462 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| BLACK DIAMOND THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2022 |
| Unternehmen | Position | Ende |
|---|---|---|
| NUVATION BIO INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.02.2022 |
| IMMUNE DESIGN CORP | Technik-/Wissenschafts-/F&E-Leiter | 02.04.2019 |
| CLOVIS ONCOLOGY, INC. | Corporate Officer/Principal | 01.09.2016 |
The Rockefeller University
 The Rockefeller University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Hoffman-La Roche, Inc.
 Hoffman-La Roche, Inc. Pharmaceuticals: MajorHealth Technology Researches, develops and manufactures medicines, diagnostics and vitamins | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 9 |
|---|---|
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology Develops novel therapeutic products and blood cell growth factors for the treatment of cancer | Health Technology |
The Rockefeller University
The Rockefeller University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immune Design Corp.
 Immune Design Corp. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical and clinical-stage immunotherapy company | Health Technology |
Russian State Medical University
 Russian State Medical University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Clovis Oncology, Inc.
 Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as an biopharmaceutical company that acquires, develops and commercializes innovative anti cancer agents | Health Technology |
Hoffman-La Roche, Inc.
Hoffman-La Roche, Inc. Pharmaceuticals: MajorHealth Technology Researches, develops and manufactures medicines, diagnostics and vitamins | Health Technology |
Research Institute for Pediatric Oncology
 Research Institute for Pediatric Oncology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Black Diamond Therapeutics, Inc.
 Black Diamond Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops precision medicines for cancer | Health Technology |
Nuvation Bio, Inc.
 Nuvation Bio, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops oncology related novel therapeutic candidates | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
Wählen Sie MarketScreener 
